The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Geron plans to sell more stock; shares slip

December 6, 2010 12:45 pm | by The Associated Press | News | Comments

Geron Corp., which develops treatments for cancer and other diseases, said Monday it plans to sell an undisclosed amount of stock to the public.The shares fell sharply in extended trading.Geron said the plan was subject to market conditions and it couldn't guarantee the size or terms of the...

Cephalon CEO on indefinite medical leave

December 6, 2010 12:45 pm | by The Associated Press | News | Comments

Biotechnology company Cephalon Inc. said Monday that Chairman and CEO Frank Baldino Jr. will not be resuming his duties at the company in 2010 and will remain on a medical leave of absence indefinitely.In August, the company said Baldino took a medical leave, but did not provide additional...

DFG establishes 10 new research training groups

December 6, 2010 11:34 am | by EurekAlert | News | Comments

(Deutsche Forschungsgemeinschaft) In order to further strengthen the position of early career researchers in Germany, the Deutsche Forschungsgemeinschaft is establishing 10 new research training groups. This decision has just been taken by the relevant DFG grants committee in Bonn.


JCI online early table of contents: Dec. 6, 2010

December 6, 2010 10:36 am | by EurekAlert | News | Comments

(Journal of Clinical Investigation) This release contains summaries, links to PDFs, and contact information for the following newsworthy papers to be published online, Dec. 6, 2010, in the JCI: "Alpha-2 integrin: a protein predictor of tumor spread?;" "A DEDD cert to support embryo...


NaviNet buys mobile health IT firm Prematics

December 6, 2010 10:35 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Health information technology firm NaviNet has bought Prematics Inc, a provider of mobile health IT solutions for doctors. Cambridge-based NaviNet said the acquisition of Virginia-based Prematics would enable the company to extend its services to physicians using handheld devices.

Researchers create new high-performance fiber

December 6, 2010 10:35 am | by I-Micronews | News | Comments

Researchers at Northwestern University have nanoengineered a new kind of fiber that could be tougher than Kevlar.

Ventas wraps $186M deal for senior housing assets

December 6, 2010 8:45 am | by The Associated Press | News | Comments

Real estate investment trust Ventas Inc. said Monday it has completed a $186 million buyout of 58 senior housing communities from affiliates of Sunrise Senior Living Inc.Ventas initially had between 15 percent and 25 percent ownership in the communities. The deal gives Ventas full ownership in...

A DEDD cert to support embryo development

December 6, 2010 8:36 am | by EurekAlert | News | Comments

(Journal of Clinical Investigation) Before the placenta is established, a structure that is key to supporting embryonic development forms in the uterus. Defective formation of this structure is thought to be a cause of female infertility. Researchers have now determined that the...


Health care reform still divisive

December 6, 2010 8:35 am | by Mass High Tech: The Journal of New England Technology | News | Comments

While 40 percent of Americans want to repeal all or most of last year's health care reform bill, 31 percent want all or most of the reforms. In a Harris Interactive Poll conducted in partnership with Norwalk, Conn.-based HealthDay, the results indicate that people across the nation remain...

FDA grants study of Abiomed heart device

December 6, 2010 8:34 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Cardiac medical device maker Abiomed Inc. has won conditional approval from the U.S. Food and Drug Administration for a pilot study to test its Impella 2.5 device reducing heart muscle damage in patients with ST-elevation myocardial infarction (STEMI).

ArQule begins trial of cancer drug candidate

December 6, 2010 8:33 am | by Mass High Tech: The Journal of New England Technology | News | Comments

ArQule Inc. has enrolled its first patient in a Phase 1 clinical trial aimed at testing ARQ 736, its small molecule inhibitor of the RAF kinases, ArQule officials announced today in a press release.

KLS Martin's SonicWeld Rx Changing the Face of Craniomaxillofacial Plate Fixation

December 6, 2010 7:34 am | by Bio-Medicine.Org | News | Comments

TORONTO, Dec. 6, 2010 /- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, US craniomaxillofacial plate and screw market growth will be driven by uptake of new resorbable polymers and novel implantation techniques. KLS Martin's...


diaDexus to Present at the Canaccord Genuity Healthcare Conference

December 6, 2010 7:34 am | by Bio-Medicine.Org | News | Comments

SOUTH SAN FRANCISCO, Calif., Dec. 6, 2010 /- diaDexus, Inc. (OTC Bulletin Board: DDXS ), a diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, today said that it plans to...


CTCs Predict Poor Outcome From Blood Stem Cell Transplantation Therapy for Metastatic Breast Cancer

December 6, 2010 7:34 am | by AACR | News | Comments

• High-dose chemotherapy and autologous stem cell transplantation is effective therapy. • Therapy may release cancer stem-like cells from bone marrow. • Patients who had low circulating tumor cells did well. SAN ANTONIO - Metastatic breast cancer patients who had circulating tumor cells...


In the Treatment of COPD, Greater Use in the Primary Care Setting Will Strengthen Spiriva's Position Among Sales Leaders

December 6, 2010 7:33 am | by Bio-Medicine.Org | News | Comments

BURLINGTON, Mass., Dec. 6, 2010 /- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Boehringer Ingelheim/Pfizer's Spiriva will most likely strengthen its position among the sales leaders for the treatment of...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.